By Catherine Eckford (European Pharmaceutical Review)2025-04-17T12:54:54
Findings from the proof-of-concept study highlight the safety of the novel delivery system for patients who are ineligible for standard intravenous cell therapy.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-30T10:47:00Z
Sponsored by CPhI
2026-04-14T12:32:00Z
Sponsored by Thermo Fisher Scientific
2026-04-14T12:29:00Z
Sponsored by JRS Pharma, In association with Vetter Pharma
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-02-09T10:00:00 2026-02-09T11:00:00
Sponsored by Emerson
2025-09-19T15:46:00
Sponsored by ACCI, By European Pharmaceutical Review
2025-07-10T12:58:00
Sponsored by FUJIFILM Wako Pure Chemical Corporation
2025-11-20T15:00:00
Sponsored by Rapid Micro Biosystems
Site powered by Webvision Cloud